Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find news

All 400 news items, newest first.

Free to read, “May need a subscription” and “Archived copy”: what they mean

Whether an article is free to read is a guess, not a test of your access. Each item is one of three:

  • No label: free to read (341 of 400). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
  • May need a subscription (15 of 400). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
  • “Free to read? Not known” (44 of 400). The outlet is on neither list and its page said nothing. We do not call these paywalled.

Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 288 of 400 items have one.

Minnesota Paid Leave Program Launches Statewide January 1, 2026, Covering Leave to Care for an Ill Family Member

Minnesota Department of Employment and Economic Development (DEED); Minnesota Department of Revenue Policy

The Minnesota Department of Employment and Economic Development (DEED) and Gov. Tim Walz announced that the state's Paid Leave program, created by a 2023 law, launches statewide on January 1, 2026, providing eligible workers paid, job-protected time off for major life events including caring for an ill family member. Early applications for 2025 births opened Dec. 3, 2025; up to 20,000 Minnesotans were expected to apply in December and January. Small employers pay reduced premium rates and may qualify for grants to cover staffing costs during an employee's leave. The Minnesota Department of Revenue separately states that beginning January 2026 the program provides eligible individuals with medical or family leave.

Why it matters: Minnesota's statewide Paid Leave program launches January 1, 2026, providing eligible workers with paid, job-protected time off for major life events, including caring for an ill family member.

Read at Minnesota Department of Employment and Economic Development (DEED); Minnesota Department of Revenue → Archived copy (24 Feb 2026), Internet Archive

New AI technology can provide rapid and reliable dementia diagnosis

Medical Xpress Diagnosis

Researchers at Örebro University have developed two new AI models that can analyze the brain's electrical activity and accurately distinguish between healthy individuals and patients with dementia, including Alzheimer's disease.

Why it matters: Researchers developed AI models analyzing brain electrical activity to distinguish healthy individuals from dementia and Alzheimer's patients.

Read at Medical Xpress → Archived copy (28 Nov 2025), Internet Archive

Pill form of semaglutide fails to slow Alzheimer's in large trial

Medical Xpress Research

A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.

Why it matters: A pill form of semaglutide failed to slow Alzheimer's disease progression in a large trial, Novo Nordisk announced on Nov. 24.

Read at Medical Xpress → Archived copy (6 Jan 2026), Internet Archive

Novel discovery reveals how brain protein OTULIN controls tau expression and could transform Alzheimer's treatment

Medical Xpress Research

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the protein that forms toxic tangles in Alzheimer's disease. …

Why it matters: Scientists uncovered a surprising mechanism by which the brain enzyme OTULIN controls tau expression, which could transform Alzheimer's treatment.

Read at Medical Xpress → Archived copy (25 Nov 2025), Internet Archive

Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release

Alzheimer's Association Research

Novo Nordisk's EVOKE and EVOKE+ Phase 3 trials of oral semaglutide in more than 3,800 people with early symptomatic Alzheimer's did not meet the primary endpoint of significantly slowing disease progression, despite improving some Alzheimer's-related biomarkers. Novo Nordisk ended its Alzheimer's trials for semaglutide, including the injectable version.

Why it matters: A high-profile failure for the theory that GLP-1 weight-loss drugs could treat Alzheimer's, dampening near-term hopes for repurposing this popular drug class for dementia.

Read at Alzheimer's Association → Archived copy (30 Jul 2026), Internet Archive

J&J's Novel Alzheimer's Drug Fails in Key Trial, Dimming Hopes for a Hot Target

STAT News Research

Johnson & Johnson terminated its mid-stage trial of posdinemab, a tau-targeting antibody, after an early analysis showed it was not outperforming placebo in slowing Alzheimer's progression.

Why it matters: A setback for the broader strategy of targeting tau protein rather than amyloid, a drug class also being pursued by Biogen, UCB, and Voyager Therapeutics.

May need a subscription Based on the outlet (STAT), not a check of this article.

Read at STAT News → Archived copy (1 Mar 2026), Internet Archive

APOE gene raises delirium risk even without dementia, global analysis reveals

Medical Xpress Research

A major genetic risk factor for delirium has been identified in a study that analyzed the DNA of more than 1 million people worldwide.

Why it matters: A study analyzing DNA from over 1 million people worldwide identified a major genetic risk factor for delirium.

Cited in this article, summarized in alzhub's library:
Read at Medical Xpress → Archived copy (25 Feb 2026), Internet Archive

Genetic risk combined with cardiovascular factors may help predict and delay dementia

Medical Xpress Research

Combining genetic risk with cardiovascular disease risk factors—such as high LDL cholesterol, obesity, and hypertension—may predict who is more likely to develop dementia, according to a new study led by UC San Francisco.

Why it matters: Combining genetic risk with cardiovascular disease risk factors—such as high LDL cholesterol, obesity, and hypertension—may predict who is more likely to develop dementia.

Read at Medical Xpress → Archived copy (22 Jan 2026), Internet Archive

Simple blood test may someday allow for diagnosis of LATE dementia during life

Medical Xpress Research

Jijing Wang, Ph.D., and Hyun-Sik Yang, MD, of the Department of Neurology at Mass General Brigham, are the lead and senior authors of a paper published in Molecular Neurodegeneration titled "Plasma TDP-43 is a potential biomarker for advanced limbic-predominant…

Why it matters: A simple blood test measuring plasma TDP-43 may someday enable doctors to diagnose advanced LATE dementia during a patient's life.

Read at Medical Xpress → Archived copy (21 Nov 2025), Internet Archive

How AI can create a virtual programmable human and revolutionize drug discovery

Medical Xpress

From idea, to lab, to clinic, to approval—it's a long and expensive process to bring a drug to market. It also rarely succeeds.

Why it matters: AI can create a virtual programmable human and revolutionize drug discovery, which is key because bringing a drug to market is a long, expensive process that rarely succeeds.

Read at Medical Xpress → Archived copy (17 Dec 2025), Internet Archive

Last updated